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Abstract: The studies were undertaken to evaluate feasibility of pulmonary delivery of 
liposomaly encapsulated tacrolimus dry powder inhaler for prolonged drug retention in lungs 
as rescue therapy to prevent refractory rejection of lungs after transplantation. Tacrolimus 
encapsulated liposomes were prepared by thin ﬁ  lm evaporation technique and liposomal disper-
sion was passed through high pressure homogenizer. Tacrolimus nano-liposomes (NLs) were 
separated by centrifugation and characterized. NLs were dispersed in phosphate buffer saline 
(PBS) pH 7.4 containing different additives like lactose, sucrose, and trehalose, and L-leucine 
as antiadherent. The dispersion was spray dried and spray dried powders were characterized. In 
vitro and in vivo pulmonary deposition was performed using Andersen Cascade Impactor and 
intratracheal instillation in rats respectively. NLs were found to have average size of 140 nm, 
96% ± 1.5% drug entrapment, and zeta potential of 1.107 mV. Trehalose based formulation 
was found to have low density, good ﬂ  owability, particle size of 9.46 ± 0.8 μm, maximum ﬁ  ne 
particle fraction (FPF) of 71.1 ± 2.5%, mean mass aerodynamic diameter (MMAD) 2.2 ± 0.1 
μm, and geometric standard deviation (GSD) 1.7 ± 0.2. Developed formulations were found to 
have in vitro prolonged drug release up to 18 hours, following Higuchi’s Controlled Release 
model. In vivo studies revealed maximal residence of tacrolimus within lungs of 24 hours, 
suggesting slow clearance from the lungs. The investigation provides a practical approach for 
direct delivery of tacrolimus encapsulated in NLs for controlled and prolonged retention at 
the site of action. It may play a promising role as rescue therapy in reducing the risk of acute 
rejection and chronic rejection.
Keywords: lung transplant rejection, tacrolimus, nano-liposomes, spray drying, dry powder 
inhaler
Introduction
Lung transplantation (LT) is a widely accepted technique for the treatment of end-stage 
pulmonary disease (Letsou et al 1999). Short-term outcome after LT has improved 
signiﬁ  cantly over the last decade, but long-term survival remains limited by the devel-
opment of bronchiolitis obliterans syndrome, which is believed to be a manifestation 
of chronic allograft rejection and occurs in 30% to 50% of patients at 2 years after LT 
(Boehler et al 2000; Hertz et al 2002). The acute rejection is the primary risk factor 
for bronchiolitis obliterans syndrome (Boehler et al 2000; Hertz et al 2002).
The cyclosporine is administered either orally or systemically in prevention and 
treatment of acute and chronic transplant rejection and found 1-year survival rates 
to reach 70% (Hosenpud et al 1996). Unfortunately, many patients still suffer from 
signiﬁ  cant morbidity and mortality, primary graft failure, acute and chronic rejec-
tion, (Grifﬁ  th et al 1994) and severe cardiovascular, hepatic, renal complications 
(Lubetkin et al 1996). Because the severity, frequency, and duration of acute rejection 
have been linked to the risk of chronic allograft rejection, controlling persistent or International Journal of Nanomedicine 2007:2(4) 676
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recurrent acute rejection is paramount (Horning et al 1998). 
However, long-term results are not optimal; improved 
methods of immunosuppression and new therapeutic agents 
are constantly under investigation for better control of the 
situation. In LT recipients, because of the high risk of LT 
rejection the optimal selection, dosage and delivery of 
immunosuppressants is critical (Reams et al 2002).
Tacrolimus a primary immunosuppressant found to be 
effective, potent, safe and superior than cyclosporine and 
showed promising results in reducing risk of acute rejec-
tion and obliterative bronchiolitis in LT (Grifﬁ  th et al 1994; 
Onsager et al 1999; Treede et al 2001) and lower toxicity 
(Knoop et al 2005). LT recipients with refractory rejection 
or intolerance or resistant to conventional immunosuppres-
sant, steroid and antibody-resistant rejection may respond to 
rescue therapy with tacrolimus (Mentzer et al 1998; Flynn 
et al 2001). Currently, there is no consensus among the lung 
transplant community regarding the optimal immunosuppres-
sive regimen, but there is a trend towards more frequent use 
of the tacrolimus (Wagner et al 1997). The clinical utility of 
tacrolimus is hindered due to dose-related efﬁ  cacy and tox-
icity, narrow therapeutic index, potential drug interactions, 
and large inter-/intra-patient variability in pharmacokinetics 
of available oral or parental formulations (Ihara et al 1995). 
To overcome these constraints various novel formulations 
have been developed, such as cyclodextrin complexes (Arima 
et al 2001), biodegradable microspheres (Wang et al 2004), 
liposomes (Cañadas 2004; Alemdar et al 2004) etc.
Another possibility for improving the clinical results 
in LT is the application of currently used medications via 
an aerosolized route (Waldrep 1998). Although aerosolized 
immunosuppressant formulations is not commercially avail-
able at present, the administration of aerosolized cyclosporine 
after LT improved survival and decreased chronic rejection 
due to local immunosuppressive effect with minimal systemic 
toxicities (Iacono et al 1996; Arppe et al 1998; Letsou et al 
1999). Pulmonary administration has expanded the potential 
for more effective utilization with an array of potent and 
effective immunosuppressant in prevention of acute and 
chronic rejection in LT. The utilization of liposomes for 
aerosol delivery has many potential advantages, including 
universal carrier suitability for most lipophilic drugs, aqueous 
compatibility, sustained release or depot and intracellular 
delivery (Waldrep 1998). Among pulmonary drug delivery 
systems, dry powder inhaler formulations (DPIs) stand out 
because of the stability of drugs and formulations (Prime et al 
1997). Liposomal drug DPIs have many promising features 
for pulmonary administration particularly with respect to 
the controlled delivery, increased potency, reduced toxicity, 
can uniformly deposit drugs locally, propellant free, patient 
compliance, high dose carrying capacity, stability, patent 
protection (Letsou et al 1999; Joshi and Misra 2001, 2003; 
Shah and Misra 2004; Lo et al 2004; Lu and Hickey 2005; 
Vermehren et al 2006).
To the best of our knowledge, this is the only literature 
explaining the use of nano-liposomal delivery of tacrolimus 
to provide prolonged drug release directly to the lungs. 
Therefore, the aim of this study was to encapsulate tacroli-
mus within NLs, incorporate NLs into DPIs by spray dry-
ing and to evaluate in vitro and in vivo performance of the 
developed DPIs for drug release, pulmonary deposition, and 
fate of drug in lungs. It was hypothesized that spray dried 
NLs DPIs will provide stable, high aerosolization efﬁ  ciency 
to deep lungs, prolonged drug release, slow systemic dilu-
tion, and avoid macrophage uptake of encapsulated drug by 
carrier based delivery of nano-range liposomes. Hence, it is 
expected to provide synergistic combinations of localized 
and sustained action within the lungs to provide multisite 
immunosuppression; thereby may enhance acceptance of 
transplanted lungs by the patient and reduce associated 
systemic toxicities.
Materials and methods
Materials
Tacrolimus was received as a gift from Concord Biotech Ltd 
(Ahemedabad, India), Hydrogenated phosphatidylcholine 
(HSPC), and cholesterol was obtained from Lipoid (Lipoid 
GmBH, Ludwigshafen, Germany) and S. D. Fine chemicals 
(Vadodara, India) respectively. L-leucine was received as 
a gift from Alembic limited (Vadodara, India). Dialysis 
Bag (mol. cut off weight 10,000) was obtained from Sigma 
Chemical Co. (Milwaukee WI 53209, United States). Inhala-
tor brev I. S. F. was provided by Panacea Biotec Ltd, Lalru, 
Punjab, India for this research studies. All chemicals were 
of an analytical grade or spectroscopic grade.
Preparation of tacrolimus loaded 
liposomes
Nanosize liposomes of tacrolimus were prepared by medica-
tion of thin ﬁ  lm evaporation technique (New 1990). 42 mg 
tacrolimus, HSPC and cholesterol (8:2) was dissolved in a 
mixture of methanol and chloroform (2:1) which was sub-
jected to dry thin ﬁ  lm formation in Rotaevaporator using 
500 ml quick ﬁ  t round bottom ﬂ  ask at 100 rpm, for a time 
duration of half hr, under 250 mm Hg at 65 °C temperature. International Journal of Nanomedicine 2007:2(4) 677
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The liposomes were hydrated using 30 ml of PBS pH 7.4 for 
a period of 1 hr. The liposomal dispersion was passed through 
high-pressure homogenizer (Emulsiﬂ  ex®-C5, Avestin Inc., 
Ottawa, Canada) pre-heated to 65 °C using thermostat for 
two cycles at 10,000 psi for size reduction. Resultant NLs 
were subjected to centrifugation at 30,000 rpm, 20 °C for 
20 minutes using ultracentrifuge (Sigma Laboratory centri-
fuge, 3K 30, Osterode, GmBH). NLs pellets were separated 
and washed twice with 20 ml PBS pH 7.4 and centrifuged 
to separate NLs. The NLs pellets were separated and char-
acterized for vesicle size, zeta potential and percent drug 
entrapment. Further, percent drug entrapment within NLs and 
un-entrapped drug content from supernatant were analyzed 
by HPLC method.
Spray drying of nano-liposomal dispersion
The NLs equivalent to 40 mg of tacrolimus were dispersed 
in 200 ml PBS containing 20 mg/ml additive (lactose/su-
crose/ trehalose), and 12% of L-leucine based on the weight 
of the powder at room temperature. Similarly, 40 mg of 
plain TL was dissolved in 200 ml methanolic PBS contain-
ing lactose (20 mg/ml) and 12% of L-leucine. Dispersion 
were ﬁ  ltered (1 μm) prior to spray drying and immediately 
used. A laboratory spray-dryer (LSD-48, JISL, Mumbai, 
India) was used for spray drying. Feed was pumped into the 
drying chamber at a rate of 1.7 ml/min and pneumatically 
atomized through a 0.7 mm nozzle using aspiration at 100% 
and atomization air at 2.0 kg/cm2. The inlet temperature was 
set at 110 °C ± 5 °C with an outlet temperature of 60 °C to 
65 °C. The resultant powder was blown through the cyclone 
separator and collected in a receiving vessel. After the 
spray process, the product was ﬁ  lled into vials in a mois-
ture free atmosphere. The spray dried powders equivalent 
to 200 ± 40 μg were ﬁ  lled in Quali-V®, a hydroxypropyl 
methylcellulose (HPMC) capsule of size 2 (Shionogi Quali-
caps, S.A., Spain). These capsules were prepared for in vitro 
aerosolization studies.
Assay
Tacrolimus was estimated by dissolving equivalent quan-
tity of formulations containing 500 μg of TL in methanol 
and passed through a 0.22 μm syringe ﬁ  lter before sample 
injections. The drug content was determined by using a 
Dionex HPLC system (Dionex Soffron GmbH, Germany) 
with UV detection. The HPLC system was composed of a 
pump (P-680, Dionex), a simple 20-μl loop injector (Reo-
dyne 7125) and a UV spectrophotometric detector (UVD 
170U, Dionex). The separation was carried out on a C18 
column (Thermo Electron Corporation, Bellefonate, PA, 
USA) maintained at 65 °C using column oven having 4.6 
by 25 cm (internal diameter) and particle size of 10 μm. 
The mobile phase comprise of water: acetonitrile: methanol 
(40:30:30 v/v) at a ﬂ  ow rate of 0.9 ml/min. The wavelength 
of the detector was 210 nm. The data was analyzed by 
Chromleon 6.5 software. The calibration curve of tacroli-
mus was prepared in each assay in a concentration range 
from 0 to 50 μg/ml. The correlation coefﬁ  cient was always 
more than 0.99, and a detection limit of quantiﬁ  cation was 
0.5 μg/ml. The concentration of tacrolimus below detec-
tion levels was determined by spiking test solution with 
standard solution.
Particle size and zeta potential 
measurement
The size of tacrolimus NLs was measured by dynamic light 
scattering with a Malvern Zetasizer 3000 HS (Malvern 
Instruments, Malvern, UK- Sun Pharmaceutical Advanced 
Research Centre, Vadodara, Gujarat, India). The zeta po-
tential was calculated by Smoluchowski’s equation from 
the electrophoretic mobility of TL-loaded liposomes at 
25 °C (Mu and Feng 2001). The particle sizes of spray dried 
formulations were assessed by dispersing them in isopropyl 
alcohol to achieve an obscuration between 10%–20% at a 
stirring speed of 1000 rpm based on laser diffraction using 
Malvern MasterSizer SM 2000K (Malvern Instruments 
Inc., UK). The measurements were recorded in triplicate. 
The results were for volume mean diameter (VMD), which 
related to the mass median diameter by the density of the 
particles. Span value is deﬁ  ned from the polydispersibility 
of powder.
Percent drug entrapment/retention
Percent drug entrapped was analyzed by solubilizing NLs 
in 0.1% Triton X-100 in methanol. The drug retained in 
spray dried formulation was determined after rehydration 
of powder equivalent to 200 ± 40 μg of TL in PBS and 
rehydrated NLs were separated by centrifugation at 35,000 
rpm, 20 °C for 20 minutes. NLs were treated with 0.1% Triton 
X-100 in methanol and the resultant solutions were diluted 
with mobile phase for HPLC analysis.
Solid state characterization
Tapped density was evaluated by mechanically tapping a 
measuring cylinder containing 10 g of powder sample. After 
observing the initial volume, the cylinder was mechani-
cally tapped, and volume reading was taken until little to no International Journal of Nanomedicine 2007:2(4) 678
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change in volume was observed. The plateau condition was 
obtained after 500 taps for all samples. The pile was care-
fully built up by dropping the material through a funnel till 
the tip of the funnel (height, 2 cm). The angle of repose was 
calculated by inversing tangentially the ratio of height and 
radius of the formed pile. The Carr’s compressibility index 
was calculated.
The residual water content of the formulations (50 mg) 
was determined using Automatic Karl-Fischer Titrator 
(Chemito CL 48885, Mercury Labs, Baroda). Commercially 
available pyridine free reagent was standardized with known 
quantity of water (250 mg).
Surface morphology and topographical 
features
The surface morphology was examined by scanning electron 
microscopy (SEM) (JSM-5610LV, JEOL, Japan). Powder 
samples were adhered to sample stubs using double sided 
tape, and then viewed using an accelerating voltage of 15 
kilovolt at the magniﬁ  cation of 250X to 5000X. Image 
analysis software (Image Proplus 5.0, Media Cybernetics, 
USA) was used to assess surface texture and topographical 
features. Image analysis of the SEM pictures was conducted 
on a ﬁ  xed area selected on the particle ﬂ  at base in order to 
avoid tilting angle shadow effect. Various topographical 
parameters were also calculated as described below:
Roundness: Reports the roundness of each object, as 
determined by the following formula: (perimeter2)/(4 * Π 
* area).
Aspect ratio: Reports the ratio between the major axis 
and the minor axis of the ellipse equivalent to the object (ie, an 
ellipse with the same area, ﬁ  rst and second degree moments), 
as determined by Major Axis/Minor Axis. Three dimensional 
surface plots, which describe the surface topography of 
particles, were drawn by scanning on the selected area of the 
image, an up and down, line showing the variability of gray 
level as a function of the position. Ten surface plots were 
drawn on each image and topographical features viz. fractal 
dimension, heterogeneity, and clumpiness; the descriptors 
of the texture of the surface were calculated and are deﬁ  ned 
as follows
Fractal dimension: Calculated as 1 minus the slope 
of the regression line obtained when plotting the log of the 
perimeter (using a particular stride) against the log of the 
stride length, as calculated with multiple starting points in 
the outline for the strides.
Heterogeneity: Reports the fraction of pixels that vary 
more than 10% from the average intensity of the object.
Clumpiness: Derived from heterogeneity measure-
ment; the fractions of heterogeneous pixels remaining in 
an object after an erosion process. It reﬂ  ects the object 
texture.
Differential scanning calorimetry
The thermal properties of formulations were analyzed 
using differential scanning calorimetry (Mettler DSC 
20, Mettler Toledo, Switzerland- Panacea Biotec Ltd, 
Lalru, Punjab, India) and the thermograms were analyzed 
using Mettler Tolerdo Star system. An empty aluminum 
pan was used as the reference for all measurements. A 
sample (2–4 mg) of sample was placed in hermetically 
sealed aluminum pan and scanned at a rate of 10 °C/min 
from 0 °C to 250 °C.
In vitro release studies
In vitro release studies of developed DPIs and spray dried 
plain tacrolimus with lactose (STL) were evaluated in a 
customized and validated diffusion cell across cellophane 
membrane (10,000 MCO) for 18 hours using 50 ml of 
methanolic PBS as diffusion medium. The hydrodynamic 
characteristics of the diffusion cell were established 
using the benzoic acid disc method (Mojaverian et al 
1996). The STL was dispersed in 1 ml of PBS, similarly 
developed DPIs of tacrolimus (equivalent to 15 doses; 
200 μg × 15) dispersed in 1 ml of PBS. Formulations 
to be compared were separately transferred to the donor 
compartment and stirred at 50 rpm while the receptor 
compartment was stirred at 100 rpm. 1ml of the sample 
was withdrawn from the receptor compartment at definite 
time intervals and equivalent amount of fresh medium 
was replaced to the receptor compartment. Samples were 
evaluated for tacrolimus content using HPLC method. All 
experiments were carried out in triplicates. The curve of 
percent drug released Vs time was plotted to understand 
the release behavior. To examine the drug release kinet-
ics and mechanism, the data were treated with following 
equations:
(a) Percent Drug Diffused
The percent drug diffused was determined by the formula
  Percent Drug Diffused = 
CrVr
CdVd
×100   (1)
Where,
Cr = Conc. of drug in receptor compartment.
Vr = Volume of the receptor compartment.
Cd = Conc. of drug in donor compartment.
Vd = Volume of donor compartment.International Journal of Nanomedicine 2007:2(4) 679
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(b) Kinetics of Release
The order of drug release was determined by performing 
regressions over the mean values of percent drug release 
Vs t and percent drug release Vs t.
(c) Mean Steady State Flux
The ﬂ  ux across the membrane was calculated using the 
following formula:
   JV r
dc
dt
=× ⎛
⎝
⎜
⎞
⎠
⎟
 
   (2)
Where,
J = ﬂ  ux of the drug across the membrane.
Vr = Volume of receptor compartment.
dc
dt
⎛
⎝
⎜
⎞
⎠
⎟ = Rate of change of concentration.
Mean steady state ﬂ  ux is the mean of individual ﬂ  ux 
values at all sampling points.
(d) Diffusion coefﬁ  cient
The Diffusion coefﬁ  cient of the drug at every sampling 
point was calculated using Equation no 3.
  Dc
DT
h
=× 200
2 π
     (3)
Where,
  h  = thickness of the membrane (0.02 cm)
  t  = time (sec)
  D = Diffusion coefﬁ  cient (cm2/ sec)
The diffusion coefﬁ  cient used for the discussion is the mean 
of the value (D) obtained at each sampling point.
Characterization of aerosol performance
Aerodynamic particle sizing of developed formulations was 
assessed using an eight stage, nonviable Anderson Cascade 
Impactor with a preseparator (Graseby-Andersen, Atlanta, GA, 
USA) operating at an airﬂ  ow rate of 28.3 lpm. The impaction 
plates were pre-coated with a 1.5% w/v of HPMC (4000 cps) 
gel in water to overcome particle bounce and re-entrainment 
phenomenon. A size ‘2’ Quali-V® capsule (Shionogi Quali-
caps, S.A., Spain) was ﬁ  lled with powder equivalent to 200 ± 
40 μg of tacrolimus and aerosolized using Inhalator brev I. S. 
F. Ten capsules were actuated for each impaction with each 
capsule for 10 secs. The drug content deposited in different 
parts such as induction port, preseparator, individual impaction 
plates, and powder remaining in capsule and inhaler device 
was rinsed with methanol. From drug deposition data the 
emitted dose, ﬁ  ne particle dose, FPF, MMAD, and GSD were 
calculated according to USP 27 NF 22.
Stability studies
Comparative stability studies was performed of the potential 
SLDPIT formulations at accelerated conditions (40 °C ± 
2 °C, 75% ± 5% RH), intermediate storage (30 °C ± 2 °C, 
65% ± 5% RH controlled room temperature (25 °C ± 2 °C) 
conditions as per ICH guidelines. SLDPIT formulations 
containing 200 ± 40 μg of tacrolimus was ﬁ  lled into HPMC 
capsule shells (Size “2”). These capsules were packed in HDPE 
bottles under nitrogen cover and the bottle was sealed with 
PVC coated aluminum foil. The bottles also contained silica 
bags as dehumactant and were resealed with ﬂ  ush of nitrogen 
after each sampling. Set of 50 capsules from a batch were ﬁ  lled 
in the HDPE bottles for each condition. The study was done 
with three batches of same composition. During sampling, 
one bottle containing 50 capsules was withdrawn at deﬁ  nite 
time interval, rehydrated with distilled water for 30 minutes. 
The SLDPIT formulations were also examined visually for 
the evidence of caking and discoloration. The content of the 
capsule are tested for assay, degradation, water content, PDR, 
emission and FPF.
Pulmonary pharmacokinetics
In vivo studies of promising DPIs were performed using intra-
tracheal instillations technique as per earlier reports (Joshi and 
Misra 2003), six albino rats (220–240 g; obtained from a local 
supplier) were selected in each cohort for each time interval. 
Rats were housed in individual plastic cages at a constant 
temperature and allowed free access to water and rat chow 
and prior to experimentation rats were fasted for overnight. 
Rats of either sex were selected randomly and anaesthe-
tized using urethane solution (1.2 gm/kg) by intraperitoneal 
administration. The trachea was exposed by blunt dissection 
of the sternohyoideus muscle and a small midline incision was 
made over the trachea between the ﬁ  fth and sixth tracheal rings 
using a 20 guage needle followed by cannulated with PE200 
tubing (5–7 cm) with the tip positioned approximately at the 
bifurcation of trachea. The PE50 (10–15 cm) tubing connected 
to a glass Hamilton syringe (Waters, Banglore, India) was 
inserted into the cannula up to bifurcation of the trachea. 200 
μg of tacrolimus equivalent in STL or developed DPIs were 
administered. Animals that were to be killed at 3, 6, 9, 12, and 
24 hours after administration had the cannula secured with 
sutures and the access cannula excised to leave a 1 cm protru-
sion. As control, Sham animals receiving PBS were included 
along with the experimental groups on the day of the experi-International Journal of Nanomedicine 2007:2(4) 680
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ment. BAL was performed on anaesthetized and recannulated 
animals with 12 ml PBS, prewarmed to 37 °C. To perform the 
lavage, the Hamilton syringe connected to the PE50 tubing 
was replaced with a three-way stopcock attached to two 20 ml 
syringes. Approximately 12 ml sterile (0.22 μm ﬁ  ltered) PBS 
was injected slowly in fractions to ﬁ  ll the lungs. The ﬂ  uid was 
withdrawn by gentle aspiration; this BAL yielded between 
7 – 11 ml liquid, which was centrifuged at 2000 rpm for 5 min. 
The supernatant was mixed with 1% Triton X-100 in a ratio of 
9:1 and analyzed by HPLC to determine unreleased tacrolimus. 
The lungs and portions of the trachea below the instillation 
site were excised and homogenized in 10 ml PBS containing 
1% Triton X-100. Deprotenization was performed with 10% 
sulphosalicylic acid and the tacrolimus released was analyzed 
in the supernatant after 10 times dilution with mobile phase by 
HPLC using sirolimus as an internal standard. The pulmonary 
pharmacokinetic parameters were determined using BAL and 
LH data. The mean pulmonary pharmacokinetic parameters 
were calculated on the basis of following deﬁ  nitions:
Cmax:    Maximum concentration of drug attained in lungs 
during the study ie, the drug concentration in the 
lungs is the drug estimated in LH.
Tmax:   The time point at which maximum drug concen-
tration is attained in LH (ie,the time interval of 
Cmax).
AUC24h
0:    The area under the curve of drug concentration in 
LH Vs time, over the period of study.
T1/2:   Pulmonary half-life of drug is calculated by, calculating 
the sum of the values of drug concentration in BAL 
and LH at individual sampling points, regressing the 
calculated sum over the entire duration of study and 
deriving the time point at which the sum of drug level 
is 50% compared to instilled quantity (ie, deriving the 
median of the regression line).
Statistical analysis: Each batch was prepared six times and 
data from all experiments were expressed as the mean ± stan-
dard deviation (S. D.). Data were compared using ANOVA 
and Student’s t-test and p < 0.05 was considered signiﬁ  cant.
Result and discussions
Liposomes were prepared using saturated phospholipids due 
to its physical and chemical stability compared to unsaturated 
soya phospholipids. The results of particle size distribution 
measurement are summarized in Table 1. Tacrolimus loaded 
NLs were found to have average size of 140.3 nm, span value 
of 0.47, and drug percent entrapment of 96% ± 1.5%. The 
particle size distribution pattern of NLs vesicles determined 
by Zetasizer was graphically represented in Figure 1.
The zeta potential of NLs was found to be 1.107 mV. 
Liposomal encapsulation of tacrolimus found to have 
enhanced immunosuppressant activity (Yang et al 2002). 
Nano-size range of liposome helps to achieve its uniform 
distribution in the bulk of dry powder formulations.
Characterization of spray dried NLs 
formulations
In development of novel DPIs, the spray drying technique 
offers a number of potential advantages over lyophilization 
technique (Elversson et al 2003; Bosquillon et al 2004; 
Nguyen et al 2004). Spray drying technique was utilized 
for stabilization of NLs and development of uniform par-
ticles size particles with desired properties for pulmonary 
administration to overcome constraints associated with 
lyophilization technique, such as formation of hard cake, 
need of micronization, addition of coarse carriers for aer-
solization, and heterogeneous size distribution pattern. Plain 
tacrolimus with lactose and L- leucine was also spray dried 
to compare and justify the performance of developed NLs 
DPIs. Spray drying parameters plays an important role on 
DPIs properties such as particle size, shape, topographi-
cal features, density, moisture content, and drug retention 
(Vanbever et al 1999; Elversson et al 2003). Hence, operat-
ing conditions were optimized for development of DPIs and 
operating parameters were kept constant during preparation 
of all DPIs of this investigation. Powder yield was observed 
in between 60% and 70%. Spray dried NLs with lactose 
(SLDPIL), spray dried NLs with trehalose (SLDPIT), and 
spray dried NLs with sucrose (SLDPIS) were found to have 
VMD of 10.2 ± 0.7 μm, 9.46 ± 0.8 μm, and 12.4 ± 0.9 μm 
respectively, whereas STL was found to have VMD of 8.4 
± 1.1 μm (Table 1).
Non signiﬁ  cant effect (p < 0.05) of operational param-
eters was observed on particle size distribution of developed 
DPIs using different carriers. Above 98% of drug retention 
was found after spray drying (Table 1). Recently, research-
ers explored various novel techniques for development of 
aerodynamically light particles which resulted in maximum 
drug deposition in to the deep lung (Vanbever et al 1999; 
Steckel and Brandes 2004). Formulations having a tap den-
sity less than 0.4 g/cm3 and relatively large mean diameter 
between 5 μm to 30 μm, but pusses MMAD in the range 
of 1 μm to 5 μm. NLs DPIs developed in this investiga-
tion found to have particles size  5 μm and a tap density 
less than 0.4 g/cm3 suggestive of formation aerodynami-
cally light particles. Such DPIs were reported to be more 
capable of escaping inertial and gravitational deposition International Journal of Nanomedicine 2007:2(4) 681
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in the oropharyngeal region, and get targeted to the deep 
lung or airways (Vanbever et al 1999). The tapped density, 
ﬂ  ow properties and residual moisture content of developed 
formulations are summarized in Table 2. Trehalose based 
spray dried formulation were found to have the lowest den-
sity (0.15 ± 0.04 g/cc), good ﬂ  owability (Angle of repose 
24.9 ± 1.4o, Carr’s compressibility index 40.4 ± 1.4%), and 
low residual water content of 2.8 ± 0.3. Whereas, SLDPIL 
pusses density of 0.27 ± 0.07, angle of repose of 29.7 ± 1.6, 
Carr’s compressibility index of 36.7 ± 2.2, and residual 
water content of 4.2 ± 0.7, and SLDPIS pusses density of 
0.33 ± 0.08, angle of repose of 31.6 ± 1.7, Carr’s compress-
ibility index of 34.8 ± 2.3, and residual water content of 
5.2 ± 0.7. Developed NLs DPIs were found to have low 
density, good ﬂ  owability and low residual moisture content 
as is observed from Table 2.
Phospholipids were component of pulmonary surfactants 
and were reported to facilitate droplet formation in the 
atomization step of spray drying, decrease particle surface 
energy, powder cohesiveness, and reduce residual water 
content (Steckel and Brandes 2004). Carriers formed the 
backbone structure of the solid particles during the spray-
drying process and facilitate pulmonary delivery of NLs. An 
amino acid, L- leucine, was used as anti-adherent to prevent 
tendency of the particles to bond strongly and result into light 
particles with good ﬂ  ow behavior, deaggregation properties, 
and dose reproducibility of DPIs. Various techniques were 
used for preparing an aerodynamic light porous particle for 
enhancing FPF of therapeutics (Tsapis et al 2002; Steckel 
and Brandes 2004). In this investigation, an attempt was 
made to develop aerodynamically light particles of liposo-
mal tacrolimus having a tap density below 0.4 g/cc, mean 
geometrical diameter above 5 μm and mean MMAD of the 
particles is between 2–3 μm. Formation of aerodynami-
cally light particles may attribute to inclusion of NLs and 
L-leucine as antiadherent. Due to the hygroscopic behavior 
of sucrose, spray-drying with sucrose resulted into DPI with 
higher moisture content and larger particle size than DPIs 
with trehalose or lactose, this report is in consistence with 
earlier ﬁ  ndings (Lo et al 2004).
The SEM of SLDPIT was shown in Figure 2a and reveals 
smooth and porous surface of developed particles. Topographical 
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Figure 1 Particle size distribution pattern of liposomal vesicles determined by Zetasizer.
Table 1 Summary reports of particle size distribution, drug entrapment and drug retention of liposomal formulation (mean ± SD, 
n = 3)
Formulations  Particle size VMD (μm) Span  Drug  retention  (%)
TL NLs  0.140 ± 0.02  0.47 ± 0.1  --------
STL 8.4  ± 1.1  1.6 ± 0.3  97 ± 0.4
SLDPIL 10.2  ± 0.7  1.3 ± 0.1  98 ± 1.3
SLDPIT 9.46  ± 0.8  1.4 ± 0.1   98 ± 1.1
SLDPIS 12.4  ± 0.9  1.5 ± 0.2  98 ±1.4International Journal of Nanomedicine 2007:2(4) 682
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features such as roundness, aspect ratio, fractal dimension, het-
erogeneity, clumpiness of developed formulations were derived 
from image analysis of SEM photographs by Image Proplus 5.0 
and are shown in Table 3.
The surface texture of SLDPIT obtained from SEM using 
Image Pro Plus was presented in Figure 2b. The surface 
fractal dimension, which represents degree of particle surface 
corrugation (Chew et al 2005) was determined from the 
texture of the images of powder surfaces and is recorded 
in Table 3. Figure 2b suggests varying degrees of surface 
roughness at different locations on surface of spray dried 
powder and porous nature of the particles.
The results indicate that a SLDPIT showed lower 
roughness compared to other formulations. Higher value of 
heterogeneity and clumpiness for SLDPIL and SLDPIS and 
also suggest high degree of roughness in contrast to SLDPIT. 
These variations were probably related to the composition 
and kinetics of particle formation.
The results of DSC studies are represented in Figures 3a and 
3b. The thermogram of tacrolimus showed a broad endotherm 
at 111.8 °C (Figure 3a), whereas, in case of physical mixture 
the tacrolimus showed sharp endoderm shifted to 122.25 °C 
and another endoderm at 221.15 °C due to additives in physical 
mixture (data not shown). Interestingly, the thermogram for 
the developed formulation showed absence of corresponding 
endotherm for tacrolimus and it is suggestive of encapsulation 
of tacrolimus in developed formulation (Figure 3b).
In-vitro drug release studies
A comparison between in vitro release proﬁ  les of tacrolimus 
from different formulations was graphically represented in 
Figure 4. In vitro drug release studies showed 90% drug 
release within 6 hours form STL and 18 hours from SDPIS, 
SLDPIL, and SDPIT respectively. Statistically signiﬁ  cant 
difference (p > 0.01) was observed in between in vitro release 
patterns of spray dried NLs DPIs and STL. The in vitro drug 
release parameters are tabulated in Table 4.
The regression coefﬁ  cients (0.942–0.961) of the data of 
percent drug diffused Vs t (Table 4) suggest a linear rela-
tionship between percent drug diffused and Vs t conﬁ  rming 
that the release follows Higuchi’s controlled release model 
and that the release rate is close to ﬁ  rst order kinetics. The 
SLDPIT formulations showed more prolonged drug release 
compared to other formulations. Order of retardation of drug 
release from DPIs was found to be SLDPIT > SLDPIL > 
SLDPIS > STL. It suggests prolonged drug release from 
liposomaly encapsulated drug.
The mean ﬂ  ux values and diffusion coefﬁ  cient of the STL 
were found to be higher compared to developed formulations. 
The mean ﬂ  ux values and diffusion coefﬁ  cient of the STL was 
found to be 2.84 times and 3.05 times higher than those of SLD-
PIT, 2.17 times and 2.5 times higher than those of SLDPIL, and 
1.71 times and 2.15 times higher than those of SLDPIS respec-
tively (Table 4). This is suggestive of prolonged drug release 
DPIs of TL may play a promising role in prevention of acute and 
chronic lung transplant rejection in lung transplanted patients.
Aerosol powder performances
In this investigation, we have used ‘size 2’ HPMC capsules 
instead of gelatin capsules due to its advantages over hard 
gelatin capsules such as unaffected mechanical strength at 
low level of moisture content and does not under go cross 
a b
Figure 2 (a) Scanning electron microphotograph and (b) surface texture analysis of trehalose based spray dried formulation.International Journal of Nanomedicine 2007:2(4) 683
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Table 3 Topographical features of developed liposomal formulations measured by SEM image analysis (mean ± SD, n = 10)
Formulations  Roundness  Aspect ratio  Fractal dimension  Heterogeneity  Clumpiness
SLDPIL 1.106  ± 0.076  1.356 ± 0.210  1.129 ± 0.064  0.492 ± 0.057  0.194 ± 0.057
SLDPIT 1.015  ± 0.065  1.163 ± 0.196  0.856 ± 0.052  0.351 ± 0.051  0.109 ± 0.047
SLDPIS 1.376  ± 0.092  1.453 ± 0.209  1.341 ± 0.064  0.674 ± 0.153  0.274 ± 0.095
Table 2 Solid state characterization and residual water content of spray dried liposomal formulations (mean ± SD, n = 3)
Formulations  Tapped density (g/cc)  Angle of repose (o)  Carr’s compressibility   Residual water 
     index  content  (%)
STL 0.  8  ± 0.2   43.1 ± 2.1  26.2 ± 1.8  5.6 ± 0.5
SLDPIL 0.  27  ± 0.07   29.7 ± 1.6  36.7 ± 2.2  4.2 ± 0.7
SLDPIT 0.  15  ± 0.04  24.9 ± 1.4  40.4 ± 1.4  2.8 ± 0.3
SLDPIS 0.  33  ± 0.08  31.6 ± 1.7  34.8 ± 2.3  5.2 ± 0.7
Figure 3 Differential Scanning Calorimetric grams of developed plain tacrolimus (a) and SLDPIT (b).
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Table 5 In-vitro aerosol deposition data of spray dried liposomal formulations (mean ± SD, n = 6)
Formulations   Emitted dose (%)  Fine particle fraction (%)  Mean median   Geometric standard 
     aerodynamic    deviation 
     diameter  (μm) 
SLDPIT 82  ± 3.0  71.1 ± 2.5  2.2 ± 0.1  1.7 ± 0.2
SLDPIS 63  ± 5.5  53.7 ± 3.6  2.8 ± 0.2  2.3 ± 0.1
SLDPIL 74  ± 4  62.8 ± 3.1  2.6 ± 0.2  2.2 ± 0.1
Table 4 In vitro drug release parameters regression coefﬁ  cient (r) of the line of percent drug released Vs square root of time, mean 
ﬂ  ux and diffusion coefﬁ  cient of formulations
Formulations Regression  coefﬁ  cient ( r2 )  Mean Flux(μg/min) Diffusion  coefﬁ  cient(cm2/sec)
STL ----  42.83  1.32  E-03
SLDPIL 0.961  19.72  5.26  E-04
SLDPIT 0.957  15.05  4.32  E-04
SLDPIS 0.942  25.02  6.13  E-04
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Figure 4 In vitro release pattern of developed NLs DPIs and plain tacrolimus DPIs.
linking reaction at accelerated storage conditions. Table 5 
illustrates aerosol powder performances of developed formu-
lations assessed using in vitro lung model Andersen Cascade 
Impactor USP type II.
The efﬁ  ciency of powder recovery from the cascade 
impaction test was found to be > 92%. The weight fraction 
according to the size distribution of the aerosolized particles 
from DPIs was graphically presented in Figure 5. Each bar 
represents the powder of certain sizes collected on a deﬁ  ned 
stage of the Andersen Cascade Impactor. The comparison 
of the data indicates that signiﬁ  cant differences occurred on 
the aerodynamic diameter distribution among the different 
DPIs (p > 0.05). Shift in the deposition pattern of SLDPIT 
towards the lower stages of the impactor (stages 3–7) was 
also been noticed (Figure 5).
The results of emitted dose and FPF are compared in 
(Figures 6a and 6b). Maximum FPF of 71.1% ± 2.5% was 
observed with SLDPIT as compared to SLDPIS of 53.7% ± 
3.6% and SLDPIL of 62.8% ± 3.1% (Table 5). The emitted 
dose percentage was ranged from 63% ± 5.5% for SLDPIS 
to 82% ± 3% for SLDPIT (Table 5 and Figure 6a). SLDPIT 
found to have 1.32 times and 1.13 times enhanced FPF International Journal of Nanomedicine 2007:2(4) 685
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compared to SLDPIS and SLDPIL respectively (Table 5 
and Figure 6b). The mass median aerodynamic diameter and 
geometric standard deviation of SLDPIT are found to have 
2.2 ± 0.1 and 1.7 ± 0.2 respectively (Table 5). Statistically 
signiﬁ  cant change in the FPF was observed in the in vitro 
aerosolization performance.
Results also revealed that SLDPIT exhibited the best 
aerosol powder performance among the DPIs prepared in this 
investigation in terms of emitted dose, MMAD, FPF, homo-
geneous size distribution. Promising aersolization results of 
SLDPIT may be contributing to formation of aerodynamic 
light and large particles, low density, good ﬂ  ow properties, 
and lower moisture content. We had selected promising 
SLDPIT and SLDPIT batches for in vivo studies and SLDPIT 
batch for stability studies.
Stability studies
The physical stability of liposomal formulations is one of 
the major obstacles in commercializing formulations. 1–2 
years stability of liposomal formulations preferably at room 
temperature to be considered as pharmaceutically acceptable 
with high drug retention within liposome and non signiﬁ  cant 
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Figure 5 In vitro pulmonary deposition pattern of different spray dried liposomal formulations. Each bar represents the average of six repeats and error bars refer to S. D.
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change in particle size during storage time, hence the drug 
leakage, particle size growth, in-vitro pulmonary deposi-
tion, and emission were studied at accelerated (40 °C 75% 
RH), intermediate (30 °C 65% RH) and controlled room 
temperature (CRT – 25 °C) conditions according to ICH 
guidelines for countries falling under zone III (hot, dry) and 
zone IV (very hot, humid). The results of stability studies 
are summarized in Table 6.
The percentage of tacrolimus remained entrapped for 
SLDPIT formulations after six months accelerated stor-
age was found to be 85.71% and was below the acceptable 
level, hence as per the guideline recommendation one can 
not assign a shelf-life of 18 months. Hence, the product was 
tested on intermediate storage condition in order to assign 
a shelf-life at CRT. The product stability studies were con-
ducted for one year at intermediate storage condition. The 
assay of formulations evaluated using HPLC method under 
intermediate storage conditions was found to be 97.35%, and 
at controlled room temperature storage was 99.46%. There 
was decrease in percent drug retention with the increase 
in the temperature of storage as evident from Table 6. The 
FPF of SLDPIT formulations results were observed to be in 
parallel to the results of liposomal size on rehydration ie,on 
accelerated storage the FPF found to decrease on prolonged 
storage (ANOVA: Single Factor p  0.05). However the is 
no signiﬁ  cant deference (p  0.05) in FPF on intermediate 
and CRT storage was observed for a year (Table 6).
Pulmonary pharmacokinetics
The animal experimental protocol was approved by the 
institutional animal ethical committee of The Maharaja 
Sayajirao University of Baroda, Vadodara, India. The in 
vivo studies were conducted in this investigation to test 
the possibility of obtaining prolonged localized actions of 
liposomal tacrolimus from spray dried NLs DPIs in lungs 
and the results are represented in Figures 7a and 7b. The 
quantity of tacrolimus estimated in the LH was considered 
as the drug absorbed and available for a pharmacological 
response. The quantity of tacrolimus present in the BAL was 
considered unabsorbed drug present in the lungs and still 
available for absorption. After intratracheal instillation of 
NLs DPIs, 35.47 ± 2.1% and 27.18 ± 1.63% of administered 
tacrolimus was recovered in BAL during the ﬁ  rst 4 hours, 
eventually decreasing to 9.47 ± 1.76% and 7.09 ± 1.1 by 
12 hours for SLDPIT and SLDPIL respectively; no tacro-
limus was recovered after instillation of STL after 4 hours 
(Figures 7a and 7b). The mass balance of the tacrolimus 
between the percentage drug absorbed and percentage drug 
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later stages may have been either metabolized or systemi-
cally absorbed or both.
Conclusion
A promising in vitro aerosol performance (FPF >70%) was 
observed for developed formulation of tacrolimus loaded NLs 
DPIs suggesting high deep lung deposition of tacrolimus and it 
was also found to prolonged drug release up to 18 hours in in 
vitro. The data of in vivo studies show drug residence up to 24 
hours within the lungs and slow systemic dilution of tacrolimus. 
Prolonged and high drug residence within lungs after pulmonary 
administration of NLs DPIs is expected to provide prolonged 
local action and necessitating less frequent administration and/or 
dose of tacrolimus and eventually, reduced associated systemic 
toxicities. The investigation provides a practical approach for 
direct delivery of tacrolimus encapsulated in NLs for controlled 
and prolonged residence at the site of action. Hence, it may play 
a promising role as a rescue therapy in reducing the risk of acute 
rejection and chronic rejection after LT. However, superiority of 
tacrolimus NLs DPIs over conventional oral and parentral dosage 
forms can only be established after preclinical studies in two more 
animal species followed by extensive clinical trails.
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